化合物简介
Avibactam is a non-β-lactam β-lactamase inhibitor developed by Actavis (now Allergan) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.
基本信息
中文名称
Avibactam; 硫酸单[(1R,2S,5R)-2-(氨基羰基)-7-氧代-1,6-氮杂双环[3.2.1]辛-6-基]酯
英文名称
avibactam
中文别名
英文别名
(2S,5R)-7-Oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carbox amide、(E)-7-fluoro-3-methylhept-4-en-2-one、trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide、4-Hepten-2-one,7-fluoro-3-methyl-,(E)、trans-7-fluoro-3-methyl-4-hepten-2-one
CAS号
1192500-31-4
分子式
C7H11N3O6S
分子量
265.244
精确质量
265.037
PSA
139.61
LOGP
0.581